StockVS

Mobile-health Network Solutions (MNDR) Aktienanalyse

Gesundheitswesen

Mobile-health Network Solutions

$0.77

$-0.09 (-10.27%)

Zuletzt aktualisiert: 26. Mai 2026

Kursverlauf

Analyse

Unternehmensübersicht

Mobile-health Network Solutions operates as an investment holding company dedicated to delivering telehealth solutions, with a primary operational focus within the Singapore market. The firm functions within the broader Healthcare sector, specifically categorized under the Health Information Services industry, which implies a specialization in managing and transmitting medical data to support remote patient care. The company maintains a relatively small scale in the public markets, evidenced by a market capitalization of $3.10M and an annual revenue of $7.32M over the trailing twelve months. With an employee base of 73 individuals, these valuation and revenue figures indicate that Mobile-health Network Solutions is a micro-cap entity with limited market presence compared to large-cap peers, suggesting high sensitivity to market sentiment and specific regional regulatory developments in Singapore.

Finanzielle Gesundheit

The company reported a revenue of $7.32M for the trailing twelve months, yet this figure is accompanied by a net income of $-2,586,343 and an EBITDA of $-2,503,371. The substantial discrepancy between the positive revenue of $7.32M and the significant negative net income reveals a cost structure characterized by high operating expenses that consume the majority of generated income before taxes and interest. While the free cash flow metric is listed as N/A, the absence of this positive indicator combined with negative earnings suggests limited financial flexibility for capital expenditures or unexpected liquidity needs without external financing. The gross margin stands at 19.7%, indicating that the company retains slightly more than one-fifth of revenue after direct costs, whereas the operating margin of -22.2% and profit margin of -35.3% highlight severe inefficiencies in overhead management and overall profitability. On the balance sheet, the company holds $3.48M in cash against a debt obligation of $115,463, resulting in a debt-to-equity ratio of 1.39 which technically classifies the leverage as moderate rather than highly conservative given the negative equity position implied by the negative ROE. The current ratio is reported at 4.22, a level that typically indicates robust short-term liquidity and a strong ability to cover obligations due within one year, despite the overall earnings losses. Furthermore, the return on equity is -47.6% and the return on assets is -23.5%, metrics that explicitly reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

Bewertungsanalyse

The trailing P/E ratio is N/A due to the company's net losses, and the forward P/E is also N/A, implying that traditional earnings-based valuation models are inapplicable and that any future earnings trajectory remains unquantifiable by standard multiples. The price-to-book ratio is 0.36, a figure that indicates the market values the company's equity at significantly less than its book value, suggesting a deep discount or market skepticism regarding the quality of the company's assets. Additionally, the price-to-sales ratio stands at 0.42 and the EV/EBITDA is 0.16, which are alternative valuation metrics suggesting that the stock trades at a fraction of its sales and earnings generation potential, often seen in distressed or turnaround situations. The 52-week high is $9.01 and the 52-week low is $0.76, placing the current trading price well above the low but still representing a significant portion of the range below the high, reflecting high volatility within the micro-cap space. The beta is listed as N/A, meaning that the stock's price volatility relative to the broader market cannot be quantified using standard historical data, necessitating a risk assessment based on the inherent instability of small-cap healthcare stocks.

Growth & Income

The revenue growth year-over-year is -7.7%, while the earnings growth year-over-year is N/A due to the absence of comparable prior year earnings data for growth calculation. Since the company is currently unprofitable, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense, as the focus remains on turning the negative net income of $-2,586,343 into profitability rather than expanding earnings per share. The dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute dividends to shareholders, a common practice for firms that must reinvest all available capital, including the $3.48M cash on hand, into operations to address their operational losses. Consequently, the overall growth and income profile for Mobile-health Network Solutions is defined by a contraction in top-line revenue and a complete absence of income generation, requiring a strategic pivot to reduce the -22.2% operating margin and achieve positive cash flows.

Vergleich mit Mitbewerbern

Mobile-health Network Solutions (MNDR) ist in der Gesundheitsinformationsdienste-Branche tätig. So schneidet das Unternehmen im Vergleich zu seinen nächsten Mitbewerbern nach Marktkapitalisierung ab:

Unternehmen Ticker Marktkapitalisierung KGV
Mobile-health Network Solutions MNDR $5.52M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

Das durchschnittliche KGV der Gesundheitsinformationsdienste-Branche beträgt 57.5x. Mobile-health Network Solutions wird mit einem KGV von N/A gehandelt.

Diese Analyse wurde von KI erstellt und dient nur zu Informationszwecken. Sie stellt keine Finanzberatung dar. Daten können verzögert oder ungenau sein. Führen Sie immer Ihre eigene Recherche durch und konsultieren Sie einen qualifizierten Finanzberater, bevor Sie Anlageentscheidungen treffen.

Über Mobile-health Network Solutions

Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website, as well as Internet search engines. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics through MaNaPharma platform; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. Additionally, it offers health supplements, skincare, nutrition products and medical devices wellness, personal care; health screening packages; and online services such as medical screenings and procedures, such as serology and swab tests. The company was founded in 2009 and is headquartered in Singapore.

Die Unternehmensbeschreibung wird auf Englisch angezeigt.

Website besuchen →

Wichtige Kennzahlen

Marktkapitalisierung
$5.52M
KGV
N/A
52-Wochen-Hoch
$7.95
52-Wochen-Tief
$0.66
Durchschn. Volumen
2.68M
Beta
-1.29

Daten bereitgestellt von Yahoo Finance über yfinance. Täglich aktualisiert.

Unternehmensinfo

Börse
NASDAQ
Land
Singapore
Mitarbeiter
73